Home › Funds › Marathon Asset Management Ltd › RPRX

Marathon Asset Management Ltd position in RPRX

ROYALTY PHARMA PLC · Health Care

Marathon Asset Management Ltd reported holding 261,447 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$15.3M, representing 0.69% of its reported portfolio and ranking #43 among its reported holdings. Marathon Asset Management Ltd has disclosed RPRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)261.45K sh
Reported value held$15.26M
Portfolio Weight0.69%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Marathon Asset Management Ltd's RPRX position evolved

Marathon Asset Management Ltd first disclosed a stake in RPRX in Q3 2023 at 765,833 shares (US$20.8M). The position peaked in Q1 2024 at 792,407 shares, worth US$24.1M. Across 13 filings, Marathon Asset Management Ltd increased the stake 3 time(s), trimmed it 9 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 261,447 shares valued at US$15.3M — a reduction of -24,504 shares quarter over quarter.. Notable position changes include a 26% trim in Q3 2025 (shares rose 10% over the following quarter), a 35% trim in Q2 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 765.83K $20.78M New
Q4 2023 852.42K $23.94M Add
Q1 2024 792.41K $24.07M Reduce
Q2 2024 743.73K $19.61M Reduce
Q3 2024 762.15K $21.56M Add
Q4 2024 715.17K $18.24M Reduce
Q1 2025 646.25K $20.12M Reduce
Q2 2025 579.62K $20.88M Reduce
Q3 2025 426.07K $15.03M Reduce
Q4 2025 388.23K $15.00M Reduce
Q1 2026 440.93K $21.15M Add
Q2 2026 285.95K $16.03M Reduce
Q3 2026 261.45K $15.26M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RPRX and 13F data

RPRX (ROYALTY PHARMA PLC) is a Health Care company. 48 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RPRX

All RPRX fund holders →

FAQ

How long has Marathon Asset Management Ltd held RPRX?

Marathon Asset Management Ltd has disclosed RPRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Marathon Asset Management Ltd's current position in RPRX?

As of Q3 2026, Marathon Asset Management Ltd holds 261.45K shares of RPRX (ROYALTY PHARMA PLC), valued at $15.26M, representing 0.69% of its reported portfolio and ranking #43.

Has Marathon Asset Management Ltd been buying or selling RPRX?

In the latest 13F filing (Q3 2026), Marathon Asset Management Ltd reduced its position in RPRX. The position peaked in Q1 2024 at 792.41K shares.

Which other funds hold RPRX?

Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, ROYAL LONDON ASSET MANAGEMENT LTD, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.